Seven Fleet Capital Management LP Acquires New Holdings in Evolus, Inc. $EOLS

Seven Fleet Capital Management LP bought a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) in the 4th quarter, Holdings Channel.com reports. The fund bought 82,000 shares of the company’s stock, valued at approximately $545,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Larson Financial Group LLC lifted its holdings in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Evolus during the 4th quarter worth approximately $34,000. Wexford Capital LP acquired a new position in shares of Evolus during the 3rd quarter worth approximately $37,000. Tower Research Capital LLC TRC raised its position in shares of Evolus by 340.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after purchasing an additional 5,691 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in Evolus in the 3rd quarter valued at approximately $48,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Price Performance

NASDAQ:EOLS opened at $6.63 on Friday. The firm has a market cap of $436.65 million, a PE ratio of -9.90 and a beta of 1.34. The firm has a 50 day simple moving average of $5.92 and a 200-day simple moving average of $5.54. Evolus, Inc. has a 1-year low of $3.86 and a 1-year high of $10.20.

Evolus (NASDAQ:EOLS) last announced its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $73.14 million for the quarter, compared to analysts’ expectations of $72.52 million. During the same quarter in the prior year, the business posted ($0.30) EPS. As a group, sell-side analysts expect that Evolus, Inc. will post -0.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on EOLS. Wall Street Zen cut Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. BTIG Research restated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research report on Wednesday. Finally, Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Evolus presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.